The epidemiology of Hepatitis B, C and D in Germany: A scoping review

Steffen, Gyde; Sperle, Ida; Leendertz, Siv Aina J.; Sarma, Navina; Beermann, Sandra; Thamm, Roma; Bremer, Viviane; Zimmermann, Ruth; Dudareva, Sandra

doi:10.1371/journal.pone.0229166

Cited by 10 publications

(16 citation statements)

References 79 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Attempts were made to compensate this by including non-published articles from the RKI Epidemiological Bulletin (EpiBull) and relevant regional journals. Moreover, a manual search was performed of reference lists in the included publications of the overall scoping review on VH epidemiology ( 6 ), and 14 references were identified but none were on prevalence. Further efforts, such as conducting a search for gray literature through other sources would potentially increase the number of relevant non-published literature.…”

Section: Discussionmentioning

confidence: 99%

“…This analysis was part of a large comprehensive review covering all aspects of viral hepatitis B, D, and D epidemiology in Germany and presents data on VH prevalence until 2017 (6). With this comprehensive review, information on the baseline situation which is necessary for better monitoring of VH elimination in Germany was collected.…”

Section: Methodology-strengths and Limitationsmentioning

confidence: 99%

“…The aim of the overall scoping review was operationalised into 13 specific research questions to identify available evidence in the form of published literature on VH epidemiology in Germany (6). One of the 13 questions was "What is the prevalence of HBV, HCV, and HDV in Germany?…”

Section: Review Processmentioning

confidence: 99%

“…The detailed methods of the review are described elsewhere (6). In brief, the search and reporting methods were based on the reporting items for systematic reviews and meta-analysis extension for scoping reviews (PRISMA-ScR) and the Cochrane Collaboration (https://training.cochrane.org/handbook).…”

Section: Review Processmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review

Sperle

Steffen

Leendertz

et al. 2020

Front. Public Health

Self Cite

View full text Add to dashboard Cite

Background: One of the five strategic directions in the World Health Organization global health sector strategy on viral hepatitis 2016-2021 is to generate strong strategic information for focused action to understand the viral hepatitis epidemic and focus the response. Knowledge of national prevalence is a cornerstone of strategic information. Germany is considered to be a low prevalence country for viral hepatitis B, C, and D, however the prevalence is likely to be higher among at-risk groups. Methods: The aim of this work was to give a detailed overview of the prevalence of viral hepatitis B (HBsAg, anti-HBc), C (anti-HCV, HCV RNA), and D (anti-HDV, HDV RNA) in different population groups in Germany. Therefore, we analyzed the results of a comprehensive literature search on various aspects of the epidemiological situation of hepatitis B, C, and D in Germany. Eligible publications including information on hepatitis B, C, and D prevalence were extracted from the overall spreadsheet table and summarized and analyzed based on virus and different population groups. A quality appraisal was performed using a checklist developed by Hoy et al. to assess risk of bias in prevalence studies. Results: Overall, 51 publications were identified through the literature search. The overall prevalence of HBsAg in the general (and proxy) population ranged from 0.3 to 1.6%. Among at-risk groups, including clinical populations and health care workers, the HBsAg prevalence ranged from 0.2% (among rheumatic patients) to 4.5% among HIV positive patients. The overall prevalence of anti-HCV in the general (and proxy) population ranged from 0.2 to 1.9%. Among at-risk groups, including clinical populations and health care workers, the anti-HCV prevalence ranged from 0.04% (among health care workers) to 68.0% among people who inject drugs. Conclusions: The hepatitis B and C prevalence in the general population in Germany is low. Prevalence is high to very high among at-risk populations, however for some Sperle et al. Hepatitis B, C, and D Prevalence groups evidence was incomplete or missing completely. To reach the elimination goals in Germany and implement a targeted response, more research among at-risk groups is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodology-strengths and Limitationsmentioning

confidence: 99%

Section: Review Processmentioning

confidence: 99%

Section: Review Processmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review

Sperle

Steffen

Leendertz

et al. 2020

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…B. zur Inzidenz, Mortalität und zu Spätfolgen der Hepatitis B und C sowie zur sog. Behandlungskaskade [ 9 , 17 ]. Eine weitere Datenquelle ist die Nationale Kohorte, eine populationsbasierte deutsche Kohortenstudie, die eine Gesamtteilnehmerzahl von 200.000 Erwachsenen anstrebt.…”

Section: Introductionunclassified

Wie lässt sich die Eliminierung von Hepatitis B, C und D in Deutschland messen? Ergebnisse eines interdisziplinären Arbeitstreffens

Zimmermann

Külper-Schiek

Steffen

et al. 2020

Bundesgesundheitsbl

Self Cite

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Die Weltgesundheitsorganisation (WHO) hat 2016 eine Strategie zur Eliminierung von Hepatitis-B-, -C- und -D-Virusinfektionen verfasst und Indikatoren zum Monitoring des Fortschritts definiert. Das Robert Koch-Institut hat 2019 ein interdisziplinäres Arbeitstreffen zur Verbesserung der Datenlage veranstaltet. Ziele Ziele waren die Vernetzung der Akteure, die Erstellung einer Übersicht zu den in Deutschland vorhandenen Datenquellen zu Hepatitis B, C und D und die Diskussion methodischer Aspekte. Material und Methoden Die für Deutschland relevanten WHO-Indikatoren wurden extrahiert und es wurde bestimmt, wie diese anhand vorliegender Daten konstruiert werden können. Bei dem Arbeitstreffen mit AkteurInnen aus dem öffentlichen Gesundheitsdienst, aus Kliniken, Laboren, von Krankenkassen, Forschungsinstituten, Datenhaltern und Registern wurden in Arbeitsgruppen Erhebungsmethoden diskutiert, welche dazu dienen können, fehlende Daten zu ermitteln. Die Datenquellen und Daten wurden hinsichtlich Qualität, Vollständigkeit sowie praktischer Umsetzbarkeit evaluiert und priorisiert. Ergebnisse Für die Allgemeinbevölkerung können die Indikatoren zu Prävention, Testung, Diagnose, Behandlung, Heilung, Folgeschäden und Mortalität aus Diagnose‑, Versorgungs- und Registerdaten, Daten aus Laboren und klinischen Zentren sowie einzelnen Studien konstruiert werden. Datenquellen für vulnerable Gruppen beschränken sich auf einzelne Studien zu Drogengebrauchenden, Männern, die Sex mit Männern haben, und HIV-Ko-Infizierten. Daten für MigrantInnen, Inhaftierte und SexarbeiterInnen sind kaum verfügbar; ebenso fehlen aktuelle Daten zur Krankheitslast chronischer Hepatitisinfektionen in der Allgemeinbevölkerung. Diskussion Für alle ausgewählten Indikatoren konnten Datenquellen, ihre Besonderheiten und Limitationen identifiziert werden. Im nächsten Schritt gilt es, die entwickelten Ideen in konkrete Projekte mit einzelnen Datenhaltern umzusetzen.

show abstract